India Agrochemical Stocks 2026: PI Industries, UPL, Dhanuka, Bayer Cropscience ROCE Ranked

India's agrochemical sector sits at a structural inflection point in 2026. A multi-year China+1 tailwind is pushing global innovator companies to shift formulation and active-ingredient supply chains toward Indian manufacturers. Domestic demand — driven by normal monsoon expectations after two uneven years — is recovering. And the regulatory push for bio-pesticides and lower residue formulations is reshaping product mix across the sector.

Against that backdrop, the five major listed agrochemical stocks in India span a wide quality range: from a near-zero-debt CDMO-export compounder (PI Industries) to a heavily-leveraged global generic giant (UPL) to a compact, high-ROCE domestic-branded franchise (Dhanuka Agritech). Every figure in this analysis was pulled live from the DocStoX dataset (sourced from NSE/BSE audited annual filings) on July 10, 2026. No estimates, no modelled projections, no from-memory numbers.

ROCE Rankings: The FY26 Agrochemical Scoreboard (July 10, 2026)

All figures are from audited annual filings (DocStoX data, sourced from NSE/BSE):

• Dhanuka Agritech: 28% ROCE — highest in the group; ROE 21.17%; PE 15.88x
• Bayer Cropscience: 25% ROCE — MNC franchise with 19.93% ROE; PE 32.68x
• PI Industries: 15% ROCE — CSM/export-led with 25% EBITDA margin; PE 29.95x
• UPL: 10% ROCE — global scale, high debt, lowest returns; PE 26.11x
• Rallis India: 10% ROCE — Tata group, domestic focus; PE 35.63x

The ROCE spread from 28% to 10% is stark for a single sector. It reflects fundamentally different business models: Dhanuka's asset-light domestic-branded distribution versus UPL's capital-intensive global generic manufacturing and its still-elevated debt load from the Arysta acquisition. For investors screening India agrochemical stocks 2026, ROCE is the first-order quality filter.

Dhanuka Agritech (DHANUKA): 28% ROCE at 15.88x PE — the Quality-Value Outlier

Dhanuka Agritech is the standout finding in this analysis. At 28% ROCE, ROE of 21.17%, and a PE of just 15.88x, it offers the best quality-adjusted valuation in the group — and arguably one of the better ROCE-to-PE ratios in mid-cap India. Revenue of ₹2,035 crore, PAT of ₹297 crore (PAT margin 14.59%), and EBITDA margin of 20% come from a business that does not manufacture its own active ingredients — it licenses formulations from Japanese and European innovators, adds Indian distribution muscle, and captures the margin on branded sales through an extensive dealer network across 80,000+ retail touchpoints.

That asset-light model is the engine of Dhanuka's ROCE. Capital employed stays low because there is no large AI (active ingredient) synthesis facility. The 52-week high of ₹1,975 versus the current price of ₹1,045.9 shows the market has de-rated the stock by nearly 47% from its peak — partly on sector headwinds (agrochemical pricing correction in FY25), partly on execution concerns about new-product ramp. Market cap: ₹4,715 crore. At 15.88x PE for a business generating 28% ROCE and 21% ROE, Dhanuka is the most under-priced quality name in this group on a pure returns-to-multiple basis.

Bayer Cropscience (BAYERCROP): 25% ROCE, MNC Franchise — at a Premium

Bayer Cropscience India benefits from its parent's global R&D pipeline — receiving late-stage innovations in herbicides, fungicides, and seed treatments years before they reach Indian patent expiry. That innovation advantage translates into 25% ROCE and ROE of 19.93%. Revenue of ₹5,473 crore, PAT of ₹568 crore (PAT margin 10.38%), and EBITDA margin of 13% reflect an asset-intensive business with strong return metrics.

The EBITDA margin of 13% looks modest relative to Dhanuka's 20%, but Bayer's revenue base is 2.7x larger and the margin on its flagship herbicide and fungicide brands is supported by brand premiums that generic competitors cannot easily replicate. At PE 32.68x and market cap of ₹18,561 crore, the market prices in the MNC quality premium. The current price of ₹4,129.9 sits 36.5% below its 52-week high of ₹6,509.5 — a significant correction that may reflect both sector headwinds and parent-level concerns about Bayer AG's balance sheet globally. Market cap is ₹18,561 crore. For investors who want MNC quality in agrochemicals, Bayer is the natural benchmark.

PI Industries (PIIND): 15% ROCE but the CDMO Export Story is Structural

PI Industries is the most differentiated name in this group. Its business has two distinct legs: a domestic branded formulations distribution business and a high-margin Custom Synthesis and Manufacturing (CSM) export segment, where it manufactures patented molecules under contract for global innovator agrochemical companies. The CSM business is effectively an agrochemical CDMO — capital intensive but with long-duration, take-or-pay order books from IP-protected molecules. Revenue of ₹6,714 crore, PAT of ₹1,321 crore (PAT margin 19.68%), and EBITDA margin of 25% — the highest in this group — underline the quality of the underlying business mix.

ROCE of 15% trails Dhanuka and Bayer, but that partly reflects PI's heavier asset base (dedicated CSM manufacturing capacity for multiple long-cycle projects). ROE of 11.6% is the lowest in the group — also a function of the capital-intensive CSM build-out. The current price of ₹2,607.4 is sharply below the 52-week high of ₹4,330 — down 39.8% — a correction that has made PI's valuation significantly more accessible. At PE 29.95x and market cap of ₹39,565 crore, PI trades at the highest absolute market cap in this group. The long-term structural argument — China+1 driving CSM order books — remains intact; the stock has corrected on near-term order intake uncertainty and general sector de-rating.

UPL Limited (UPL): Global Scale, 10% ROCE, High Debt — the Turnaround Thesis

UPL is in a category of its own by scale: revenue of ₹51,839 crore (the only stock in this group with a revenue base exceeding ₹10,000 crore) makes it India's largest agrochemical company and one of the top five generic agrochemical companies globally. PAT of ₹2,220 crore (PAT margin 4.28%) and EBITDA margin of 18% reflect a business that has been through a severe pricing correction in global generic agrochemicals since FY23, compounded by the debt load from its 2019 Arysta LifeScience acquisition (approximately $4.2 billion deal).

ROCE of 10% and ROE of 5.91% are the lowest in this group — but that is a cyclical low, not a structural permanent state. UPL's free cash flow has been diverted to debt servicing; once the balance sheet deleverages, returns should structurally recover toward the mid-teens. The market has partially priced in that recovery: at PE 26.11x and market cap of ₹50,215 crore, UPL is the group's most interesting turnaround story, not its current quality leader. Current price: ₹594.75, 52-week high ₹812.2, 52-week low ₹563.15. UPL is a debt-deleveraging, volume-recovery bet — not a ROCE compounder yet.

Rallis India (RALLIS): 10% ROCE, Tata Group Backing — but Priced for More

Rallis India, the Tata Group–backed agrochemical company, has the weakest returns profile in this group: ROCE 10%, ROE 9.68%, EBITDA margin 11% — the lowest margin in the set. Revenue of ₹2,663 crore and PAT of ₹125 crore (PAT margin 4.69%) tell a story of a company in operational flux: the loss of contract manufacturing revenue from a large off-take partner a few years ago hit the P&L hard, and the recovery has been slower than the market expected. Yet at PE 35.63x — the highest multiple in this group — Rallis is priced as if a quality-ROCE business is already delivering. Market cap: ₹4,455 crore. Current price ₹229.07 against a 52-week high of ₹385.9 — a 40.6% correction from peak. The Tata parentage provides a quality backstop and balance-sheet comfort, but at 35.63x PE for 10% ROCE, the return equation currently looks unfavorable relative to Dhanuka (15.88x for 28% ROCE).

FY26 Financials: The Full Scoreboard

All figures are from NSE/BSE audited annual filings, sourced via DocStoX data (pulled July 10, 2026):

• UPL: Revenue ₹51,839 Cr | PAT ₹2,220 Cr | PAT Margin 4.3% | EBITDA Margin 18% | ROCE 10% | ROE 5.9% | P/E 26.11x | Mkt Cap ₹50,215 Cr
• PI Industries: Revenue ₹6,714 Cr | PAT ₹1,321 Cr | PAT Margin 19.7% | EBITDA Margin 25% | ROCE 15% | ROE 11.6% | P/E 29.95x | Mkt Cap ₹39,565 Cr
• Bayer Cropscience: Revenue ₹5,473 Cr | PAT ₹568 Cr | PAT Margin 10.4% | EBITDA Margin 13% | ROCE 25% | ROE 19.9% | P/E 32.68x | Mkt Cap ₹18,561 Cr
• Rallis India: Revenue ₹2,663 Cr | PAT ₹125 Cr | PAT Margin 4.7% | EBITDA Margin 11% | ROCE 10% | ROE 9.7% | P/E 35.63x | Mkt Cap ₹4,455 Cr
• Dhanuka Agritech: Revenue ₹2,035 Cr | PAT ₹297 Cr | PAT Margin 14.6% | EBITDA Margin 20% | ROCE 28% | ROE 21.2% | P/E 15.88x | Mkt Cap ₹4,715 Cr

The most striking data point: Dhanuka's PAT margin (14.6%) is 3.4x Rallis India's (4.7%) on a comparable revenue base — yet Dhanuka trades at 15.88x PE while Rallis trades at 35.63x. That valuation inversion is unusual and arguably correctable over time as the market re-rates on returns-quality.

Catalysts to Watch in H2 FY27

1. Kharif season demand recovery: A normal southwest monsoon distribution (June–September 2026) is the key volume driver across all five companies' domestic businesses. Channel restocking after two years of inventory correction should accelerate if rains are timely and geographically distributed. PI Industries, Dhanuka, and Rallis have the highest domestic revenue concentration.
2. UPL debt reduction milestones: The market watches UPL's net debt trajectory quarter by quarter. Each meaningful deleveraging step — asset sales, cash flow from operations — de-risks the equity further. The stock's re-rating from 10% ROCE to a quality-priced valuation depends almost entirely on balance-sheet trajectory, not revenue growth.
3. PI Industries CSM order book update: PI typically discloses its CSM order book at annual results. Any step-up in the order book — particularly from new molecules in the commercialisation phase with global innovators — is the primary catalyst for the stock's re-rating from its current 40% discount to its 52-week high.
4. Bayer Cropscience new product launches: Bayer AG's global R&D pipeline — including next-generation fungicides and trait-enhanced hybrid seeds — funnels innovations to the Indian subsidiary. Any large commercial launch in India of a proprietary molecule in the insecticide or fungicide space could accelerate topline and margin recovery.
5. Regulatory push for bio-pesticides: The Indian government's push to reduce chemical residues in food exports — particularly for the EU market under new maximum residue level (MRL) standards — is accelerating demand for bio-rational molecules and low-residue chemistry. Companies with bio-pesticide or integrated pest management portfolios (PI's newer registrations, Dhanuka's newer bio-range) are positioned to benefit structurally.

The DocStoX Take

India's agrochemical sector in July 2026 divides into three quality tiers when measured by ROCE:

High ROCE — Dhanuka and Bayer (28% and 25%): These two companies generate the most operating profit per rupee of capital employed. Dhanuka offers the more compelling valuation at 15.88x PE; Bayer carries a deserved MNC premium at 32.68x but has corrected significantly from its 52-week high. Both are asset-light relative to the rest of the group.

Structural quality with near-term headwinds — PI Industries (15% ROCE): The 25% EBITDA margin and 19.7% PAT margin are exceptional, and the CSM export business is a multi-year structural winner on China+1. The current ROCE of 15% reflects the capital investment phase for that export order book. At 39.8% below its 52-week high, PI has de-risked meaningfully for patient investors.

Recovery and turnaround territory — UPL and Rallis (10% ROCE each): UPL has global scale and a credible deleveraging path — but the equity is a recovery bet, not a compounder yet. Rallis carries Tata parentage at an expensive 35.63x PE for the lowest returns in the group — the valuation requires a significant earnings step-up to justify current prices.

For investors screening India agrochemical stocks 2026 on a quality-adjusted-valuation basis, Dhanuka's 28% ROCE at 15.88x PE is the most anomalous data point this analysis surfaces. Full live data, DocStoX AI verdicts, and scores for all five stocks are available at docstox.com.

---

By the DocStoX Desk — This is for informational purposes only and not investment advice. Please consult a SEBI-registered advisor before investing.